ExCellThera’s lead technology, ECT-001, receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation
23 avr. 2019 08h05 HE
|
ExCellThera
MONTREAL, April 23, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for...
Novel treatment of hemophilia: OMRF enters license agreement with Shanghai RAAS Blood Products
13 févr. 2018 15h02 HE
|
Oklahoma Medical Research Foundation
OKLAHOMA CITY, Feb. 13, 2018 (GLOBE NEWSWIRE) -- The Oklahoma Medical Research Foundation has entered a license agreement with Shanghai RAAS Blood Products Co., Ltd. Under the agreement, Shanghai...
BioForce Nanosciences Holdings, Inc. (BFNH) Moves Forward With Uplifting Requirements for OTCQB, Aggressively Pursues Take Over Targets
18 oct. 2017 09h15 HE
|
BioForce Nanosciences Holdings, Inc.
VIRGINIA BEACH, Va., Oct. 18, 2017 (GLOBE NEWSWIRE) -- BioForce Nanosciences Holdings, Inc. (OTCPINK:BFNH) announces its pursuit to uplift the Company’s tradable common shares onto the OTCQB at...
Typenex® Medical Brings Innovative Blood Irradiation Indicator to Market
06 sept. 2017 09h33 HE
|
Typenex Medical
CHICAGO, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Typenex Medical, an industry leader in medical devices and supplies, announced today it is bringing Rad-Control, a new irradiation indicator tag...
Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5(TM) Topical Gel
25 juil. 2017 07h55 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jul 25, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today...
Arch Therapeutics Presents Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017
06 juin 2017 12h25 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jun 6, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today...
Arch Therapeutics to Provide Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017
22 mai 2017 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - May 22, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be...
Arch Therapeutics to Provide Corporate Update at the 29th Annual Roth Conference on Monday, March 13, 2017
06 mars 2017 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Mar 6, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and...
Arch Therapeutics to Provide Corporate Update at the Maxim Group - Haitong Securities Healthcare Investor and Partnering Conference
27 févr. 2017 08h18 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 27, 2017) - Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic...
Arch Therapeutics, Inc. $6.1 Million Registered Direct Offering
21 févr. 2017 09h08 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Feb 21, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a developer of innovative materials as hemostatic and wound care devices, today...